FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to psychiatry, and may be used for treating and preventing disorders specified in a group consisting of depressive, affective and anxious disorders, particularly a major depressive disorder. For this purpose, a patient's therapy is added with a stage of administering a therapeutically effective amount of embryonated egg isolate.
EFFECT: group of inventions provides treating the above pathology, including by inhibiting glutamate and neurokinin 2 (NK2) receptors.
15 cl, 12 dwg, 11 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIODIARYL COMPOUNDS | 2010 |
|
RU2548918C2 |
CYCLOPROPYLPIPERIDINE GLYCINE TRANSPORTER INHIBITORS | 2005 |
|
RU2387644C2 |
COMBINATION CONTAINING DECANOIC ACID FOR TREATMENT OF EPILEPSY | 2018 |
|
RU2779202C2 |
METHOD OF REPLICATION OF INFLUENZA VIRUS IN CULTURE | 2007 |
|
RU2491339C2 |
(4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL)AMIDE 4-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER | 2008 |
|
RU2500401C2 |
METHOD FOR PRODUCING TRANSGENIC BIRDS USING EMBRYO STEM CELLS | 2007 |
|
RU2473688C2 |
COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
METHOD OF TREATING DISORDERS USING SELECTIVE NR2B SUBTYPE NMDA RECEPTOR ANTAGONIST | 2009 |
|
RU2499598C2 |
PEPTIDE ANTAGONIST OF THE NMDA RECEPTOR | 2019 |
|
RU2716258C1 |
PREPARATION FROM EGGS WITH REGENERATIVE, ANALGESIC AND ANTI-INFLAMMATORY PROPERTIES | 2012 |
|
RU2585049C2 |
Authors
Dates
2014-06-27—Published
2009-01-09—Filed